🇺🇸 FDA
Patent

US 10287355

Methods and compositions for modulating lymphangiogenesis, E.G., to treat transplant rejection, in a subject

granted A61KA61K2039/507A61K35/30

Quick answer

US patent 10287355 (Methods and compositions for modulating lymphangiogenesis, E.G., to treat transplant rejection, in a subject) held by The Regents of the University of California expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K2039/507, A61K35/30, A61K39/3955